Initial studies focused on the effects in patients with diabetes including pooling analysis of four phase 3 studies of SGLT2 inhibitors; the inclusion criteria did not mandate the presence of other comorbidities. The gene discussed is SLC5A2; the disease is diabetes mellitus.